TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23157466
Drug: Dalfampridine-ER 10
Normalized name: Dalfampridine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalfampridine-ER 10 mg twice daily
Study: 21545485
Drug: Fesoterodine 8
Normalized name: fesoterodine 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 8 mg with fluconazole 200 mg
Study: 21545485
Drug: Fesoterodine 8
Normalized name: fesoterodine 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 8 mg alone
Study: 11006189
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg lignocaine
Study: 12645862
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg lignocaine
Study: 28890326
Drug: TauroLock™‐Hep500 used
Approvals — FDA: no, EMA: no, PMDA: no
Description: TauroLock™‐Hep500 used twice per week and TauroLock™‐U25,000 once a week
Study: 24297945
Drug: Temsirolimus (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (25 mg intravenously, weekly) plus bevacizumab (10 mg/kg intravenously, every 2 weeks)
Study: 24297945
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (9 MIU subcutaneously thrice weekly) plus bevacizumab (10 mg/kg intravenously, every 2 weeks)
Study: 12543884
Drug: Balloon angioplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon angioplasty (plus medication if necessary)
Study: 11696071
Drug: 1.8 mg
Normalized name: menthol 1.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg sustained-release melatonin 0.5 h before daytime sleep episodes
Study: 16298773
Drug: 1.8 mg
Normalized name: menthol 1.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg sustained-release melatonin
Study: 9715537
Drug: Sequential follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential follow-up study
Study: 3107483
Drug: Non-steroidal antirheumatic
Normalized name: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal antirheumatic drug therapy
Study: 31760817
Drug: Two letters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two letters plus educational material and a counseling call (CC)
Study: 30224584
Drug: Brief Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Cognitive Behavioral Therapy for Insomnia (CBT-I)
Study: 28127948
Drug: Reformulated DTC
Normalized name: Tarsum Reformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated DTC capsule (Duodart®) 0.5 mg dutasteride and 0.4 mg tamsulosin
Study: 28127948
Drug: Commercial formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial formulation of dutasteride and tamsulosin
Study: 23739024
Drug: Medication for
Normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication for alcohol use disorders
Study: 19846269
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg i.v.) or Prednisone (40 mg by mouth × 2 days)
Study: 16614786
Drug: Parent training
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent training combined with child therapy (CT)
Study: 15378678
Drug: mecamylamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: mecamylamine (15 mg; oral)
Study: 15378678
Drug: scopolamine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: scopolamine (0.4 mg, s.c.)
Study: 15378678
Drug: mecamylamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: mecamylamine (15 mg) + scopolamine (0.4 mg)
Study: 11520711
Drug: roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 150 mg twice a day
Study: 11520711
Drug: roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 150 mg twice a day (in Australasian population)
Study: 22585212
Drug: Miltefosine dosing
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miltefosine dosing algorithm based on allometric scaling
Study: 22585212
Drug: Allometric dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allometric dosing algorithm for miltefosine
Study: 22585212
Drug: New allometric
Approvals — FDA: no, EMA: no, PMDA: no
Description: New allometric dosing algorithm for miltefosine
Study: 15942317
Drug: Regranex Gel
Normalized name: becaplermin Topical Gel [Regranex]
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regranex Gel
Study: 12843202
Drug: Ghrelin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin (1 micro g/Kg iv)
Study: 12843202
Drug: GHRH (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (1 micro g/Kg iv)
Study: 12843202
Drug: GHRH plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH plus Ghrelin (1 micro g/Kg iv)
Study: 10472341
Drug: GnRH analog
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH analog triptorelin (3.75 mg i.m. monthly)
Study: 10472341
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of triptorelin and aromatase inhibitor formestane (4‐OHA, 500 mg i.m. fortnightly)
Study: 8933496
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (5 g creatine monohydrate 4 times per day for 5 days)
Study: 8933496
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same dosage of a lactose placebo)
Study: 1655227
Drug: Cisplatin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (120 mg/m2) and Doxorubicin (70 mg/m2) every 3 weeks for four cycles
Study: 1655227
Drug: Cyclophosphamide (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (1000 mg/m2 every 21 days for six cycles)
Study: 1655227
Drug: Whole-abdominal radiation
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-abdominal radiation therapy
Study: 1655227
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (refusal of SLL)
Study: 26624976
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate MDPI 800 μg (total dose 800 μg)
Study: 26624976
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate MDPI 400 μg (total dose 400 μg)
Study: 26624976
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate Diskus 400 μg (total dose 400 μg)
Study: 26624976
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate MDPI 800 μg
Study: 26624976
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate MDPI 400 μg
Study: 26624976
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate Diskus 400 μg
Study: 22548646
Drug: Canagliflozin 50
Normalized name: canagliflozin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 50 mg, 100 mg, 200 mg, 300 mg daily, or 300 mg twice daily
Study: 20467641
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g amoxicillin
Study: 1819435
Drug: High-dose Edmonston-Zagreb
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Edmonston-Zagreb or AIK-C at 4-5 months
Study: 1819435
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose Schwarz at 8-10 months
Study: 7274609
Drug: MgCl2 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgCl2 (60 mmole daily)
Study: 7274609
Drug: Mg(OH)2 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg(OH)2 (60 mmole daily)
Study: 30520566
Drug: Pegbelfermin 20
Normalized name: Pegbelfermin
DrugBank: Pegbelfermin (DB15365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegbelfermin 20 mg daily
Study: 30520566
Drug: Pegbelfermin (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegbelfermin (1, 5, or 20 mg daily or 20 mg weekly)
Study: 30520566
Drug: Pegbelfermin 20
Normalized name: Pegbelfermin
DrugBank: Pegbelfermin (DB15365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegbelfermin 20 mg daily and weekly
Study: 15053242
Drug: Metyrapone test
Normalized name: Metyrapone
DrugBank: Metyrapone (DB01011)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metyrapone test (30 mg/kg orally at 23:00 h)
Study: 15842577
Drug: Valdecoxib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib (10 and 20 mg once daily)
Study: 15842577
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg three times daily)
Study: 10561336
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg on alternate days
Study: 10561336
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg/d
Study: 6362245
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nifedipine (N)
Study: 6362245
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbiddinitrate (I)
Study: 6362245
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 20 mg isosorbiddinitrate and 20 mg nifedipine (I + N)
Study: 31727687
Drug: Every 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 0.1 mL/min/1.73 m2 predicted annual fall in eGFR
Study: 30725411
Drug: Methionine-restricted total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine-restricted total parenteral nutrition (MR TPN) with chemotherapy-containing amino acid solution (AO-90)
Study: 30725411
Drug: 1-day methionine-restricted
Normalized name: methionine 1.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day methionine-restricted diet combined with cystemustine (60 mg/m2 every 2 weeks)
Study: 12622925
Drug: Percutaneous gel
Normalized name: ALCOHOL 62 mL in 100 mL PERCUTANEOUS GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous gel 17beta‐estradiol (E(2)) 1.5 mg/d plus micronized progesterone (MP) 100 mg/d
Study: 12622925
Drug: Percutaneous gel
Normalized name: ALCOHOL 62 mL in 100 mL PERCUTANEOUS GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous gel 17beta‐estradiol (E(2)) 1.5 mg/d plus medroxyprogesterone acetate (MPA) 2 mg/d
Study: 12622925
Drug: Percutaneous gel
Normalized name: ALCOHOL 62 mL in 100 mL PERCUTANEOUS GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous gel 17beta‐estradiol (E(2)) 0.75 mg/d plus micronized progesterone (MP) 100 mg/d
Study: 12622925
Drug: Percutaneous gel
Normalized name: ALCOHOL 62 mL in 100 mL PERCUTANEOUS GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous gel 17beta‐estradiol (E(2)) 0.75 mg/d plus medroxyprogesterone acetate (MPA) 2 mg/d
Study: 7851681
Drug: Chronic euglycaemic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic euglycaemic hyperinsulinaemia (+72 pmol/l) for 72-96 hours
Study: 7851681
Drug: Chronic hyperglycaemic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic hyperglycaemic hyperinsulinaemia (+78 pmol/l) for 72 hours
Study: 30120832
Drug: Serratus anterior
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serratus anterior plane block with 30 ml ropivacaine 0.375%
Study: 28477992
Drug: iNPWT (intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: iNPWT (intervention negative pressure wound therapy)
Study: 8346826
Drug: Continuous spinal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous spinal anesthesia (CSA) with 0.5% bupivacaine, initial dose 1 mL, reinjection 1 mL
Study: 8346826
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural anesthesia (CEA) with 0.5% bupivacaine, initial dose 10 mL, reinjection 5 mL
Study: 8346826
Drug: Single-dose spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose spinal anesthesia (SSA) with 0.5% bupivacaine, initial dose 3 mL
Study: 20701016
Drug: CKD screening
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD screening tests (e.g., glomerular filtration rate)
Study: 19146124
Drug: Oral B
Normalized name: bran ORAL BOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B Indicator
Study: 15990003
Drug: LCAF+CT (Late
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCAF+CT (Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy)
Study: 19753739
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day itraconazole for 3 days
Study: 19753739
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day itraconazole for 1 day
Study: 19753739
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day itraconazole for 5 days
Study: 2028586
Drug: Dexamethasone, 4
Normalized name: Dexamethasone, 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, 4 mg
Study: 2028586
Drug: Acetazolamide, 250
Normalized name: AcetaZOLAMIDE, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide, 250 mg
Study: 31280790
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral group therapy (CBGT) + 4 resilience and coping strategy sessions (total 16 sessions)
Study: 20335572
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus nadroparin (2850 IU)
Study: 20335572
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (80 mg)
Study: 7774735
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) gel (2 mg for primigravidae, 1 mg for parous)
Study: 7774735
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) gel
Study: 2274632
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg to 80 mg depending on response and side effects)
Study: 29898788
Drug: Pixatimod (PG545)
Normalized name: pidotimod
DrugBank: Pixatimod (DB19166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pixatimod (PG545) administered by intravenous (IV) infusion at a dose of up to 100 mg.
Study: 29898788
Drug: Pixatimod in
Normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pixatimod in combination with PD-1 inhibitors (e.g., nivolumab).
Study: 3229870
Drug: Nilvadipine 8
Normalized name: nilvadipine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine 8 mg
Study: 14621818
Drug: St. Thomas
Normalized name: St. Thomas lidpod
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. Thomas Hospital (ST) solution
Study: 4083859
Drug: Ampicillin with
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin with a lactobacillus preparation
Study: 4083859
Drug: Ampicillin followed
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin followed 1 h later by the lactobacillus preparation
Study: 10068928
Drug: UVA1 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UVA1 therapy
Study: 30723894
Drug: Ofatumumab 500
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 500 mg
Study: 18437442
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg daily for 6 months
Study: 15824254
Drug: Choline‐containing compounds,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline‐containing compounds, phosphocreatine, myo‐inositol, total N‐acetyl‐aspartate (tNAA), and glutamate‐glutamine concentrations in cortical gray matter (CGM)
Study: 1847240
Drug: Induction combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction combination chemotherapy (ICC)
Study: 6489410
Drug: Enprofylline 4
Normalized name: Enprofylline
DrugBank: Enprofylline (DB00824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline 4 mg/kg
Study: 6489410
Drug: Theophylline 8
Normalized name: theophylline 8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 8 mg/kg
Study: 31316682
Drug: LIPUS combined
Normalized name: Canis lupus familiaris skin
DrugBank: Canis lupus familiaris skin (DB10409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIPUS combined with TENS therapy
Study: 31316682
Drug: Only TENS
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only TENS therapy
Study: 22642657
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (0.05-0.22 U/kg)
Study: 15971720
Drug: Neuromodulation, denervation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromodulation, denervation techniques, and bladder augmentation
Study: 10583435
Drug: E2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 group (micronised oestradiol 2 mg)
Study: 10583435
Drug: E2 +
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2 + P group (E2 + trimegestone 0.5 mg)
Study: 10583435
Drug: E2 +
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2 + D group (E2 + dydrogesterone 10 mg)
Study: 8904612
Drug: Mefloquine 250
Normalized name: mefloquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 250 mg weekly for 4 weeks
Study: 1678925
Drug: Terazosin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin alone (1 to 80 mg/day)
Study: 1678925
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 to 120 mg twice daily)
Study: 1678925
Drug: Terazosin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (5 mg) plus methyclothiazide (2.5 to 5 mg)
Study: 1678925
Drug: Terazosin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin plus methyclothiazide (2.5 mg)
Study: 1678925
Drug: Terazosin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin plus methyclothiazide (5 mg)
Study: 28395936
Drug: Mepolizumab 100
Normalized name: mepolizumab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab 100 mg
Study: 20884959
Drug: Nalmefene 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 40 mg/day
Study: 21967071
Drug: Nalmefene 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 20 mg/day
Study: 10811503
Drug: Eight-hour infusion
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight-hour infusion of doxorubicin (arm A)
Study: 10811503
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of doxorubicin (arm B)
Study: 31111801
Drug: 1-day AL
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day AL initiation regimen (ALNCD + 30 mg oral aripiprazole for 1 day)
Study: 31111801
Drug: 21-day AL
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21-day AL initiation regimen (AL + 15 mg/day of oral aripiprazole for 21 days)
Study: 20520293
Drug: Ziprasidone (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (20-80 mg daily)
Study: 16192477
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of total‐body irradiation (200 cGy)
Study: 10534546
Drug: Dothiepin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin (up to 150 mg daily)
Study: 2127785
Drug: 3 million
Normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 million units of recombinant interferon alfa‐2b three times weekly for 24 weeks
Study: 2127785
Drug: 1 million
Normalized name: Nystatin 1 MILLION U Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 million units of recombinant interferon alfa‐2b three times weekly for 24 weeks
Study: 27680013
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg monotherapy (RM)
Study: 26359900
Drug: Deprexis (internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprexis (internet-based cognitive behavioural therapy programme)
Study: 29110574
Drug: Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Therapy (MT)
Study: 19027095
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and aspirin therapy
Study: 14734000
Drug: F/T-PSA ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: F/T-PSA ratio >30% with T-PSA of 3-5.99 g/ml
Study: 14734000
Drug: F/T-PSA ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: F/T-PSA ratio <10% with T-PSA of 3-5.99 g/ml
Study: 14734000
Drug: F/T-PSA ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: F/T-PSA ratio >30% with T-PSA of 6-9.99 g/ml
Study: 14734000
Drug: F/T-PSA ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: F/T-PSA ratio <10% with T-PSA of 6-9.99 g/ml
Study: 9810957
Drug: Desmopressin (DDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (DDAVP nasal spray)
Study: 2647315
Drug: MQ-F-OK therapy
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MQ-F-OK therapy